Compare Recursion Pharmaceuticals Inc (RXRX) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Uber Technologies Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Uber Technologies Inc trades at $71.78 (market cap $146.91B). The key difference: Uber Technologies Inc is far larger — about 96× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | UBER | |
|---|---|---|
Market Cap | $1.53B | $146.91B |
Sector | Health | Industrials |
52-Week High | $6.79 | $100.10 |
52-Week Low | $2.84 | $68.61 |
Enterprise Value | $946.50M | $153.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Uber's stock trades at $72.46, down 2.13% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strong revenue growth, with 2025 revenue reaching $52.02 billion and net income of $10.05 billion, though profitability margins have moderated from 2024 peaks. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Europe and cost-cutting measures like HR layoffs and AI spending caps to improve efficiency.
The outlook remains positive with an 81.67% analyst buy rating and a $107.64 consensus price target, suggesting significant upside. Key risks include execution challenges in autonomous vehicle integration, competitive pressures in key markets like India, and potential margin compression. Investors should weigh strong cash flow generation and market leadership against evolving regulatory and technological landscapes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
